BOSTON, March 5, 2025 /PRNewswire/ — Bioheng Therapeutics US LLC (“Bioheng”), a clinical-stage biotech company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug…